A Rapid Strategy for Screening High-efficiency PCSK9 Inhibitors from Ginkgo Biloba Leaves by Ligand Fishing, HPLC-Q-TOF-MS and Interdisciplinary Assay

Overview

Journal J Food Drug Anal

Specialties Nutritional Sciences
Pharmacology
Toxicology

Date 2022 Jun 13

PMID 35696112

Authors

Li Li

Meng-Lin Fan

Ya-Nan Li

Ya-Xuan Huang

Xiu-Feng Liu

Ji-Hua Liu

Affiliations

Soon will be listed here.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an attractive target for new cholesterol-lowering drug development. Here, we developed a method integrating ligand fishing, HPLC-Q-TOF-MS and interdisciplinary assay, aiming to explore potential PCSK9 inhibitors from mixtures rapidly and accurately. PCSK9 was expressed and purified firstly, and then the recombined PCSK9 was coated on the surface of magnetic beads (MBs). The PCSK9-immobilized MBs (PCSK9-MBs) were used for ligand fishing combined with HPLC and Q-TOF-MS/MS. Ginkgo biloba leaves (GBL), an herbal medicine widely used in Asia and Europe with good efficacy in treatment of hypercholesterolemia, were chosen as an illustration for ligand fishing. Two PCSK9 ligands were discovered from GBL and identified as kaempferol-3-O-rutinoside (1) and kaempferol 3-O-26″-(6‴-p-coumaroyl) glucosylrhamnoside (KCGR) (2). In order to verify fishing results and pick out more powerful PCSK9 inhibitors, molecular docking assay was further performed and KCGR was optimized to be an excellent PCSK9 inhibitor by the confirmation of affinity and activity bioassay. These results suggested that the developed approach could be applied to screen and analysis potential bioactive constituents from mixtures, which may improve the efficiency of drug discovery. Moreover, KCGR separated from GBL was expected to be a potential candidate of PCSK9 inhibitors.

References

Ramanathan A, Gusarova V, Stahl N, Gurnett-Bander A, Kyratsous C . Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. PLoS One. 2016; 11(4):e0154498. PMC: 4845998. DOI: 10.1371/journal.pone.0154498. View

He X, Zhang R, Zuo P, Liu Y, Zha X, Shan S . The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis. Eur J Intern Med. 2017; 38:52-60. DOI: 10.1016/j.ejim.2016.10.009. View

Maxwell K, Breslow J . Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004; 101(18):7100-5. PMC: 406472. DOI: 10.1073/pnas.0402133101. View

Singh B, Kaur P, Gopichand , Singh R, Ahuja P . Biology and chemistry of Ginkgo biloba. Fitoterapia. 2008; 79(6):401-18. DOI: 10.1016/j.fitote.2008.05.007. View

van Breemen R, Huang C, Nikolic D, Woodbury C, Zhao Y, Venton D . Pulsed ultrafiltration mass spectrometry: a new method for screening combinatorial libraries. Anal Chem. 1997; 69(11):2159-64. DOI: 10.1021/ac970132j. View

Abifadel M, Elbitar S, Khoury P, Ghaleb Y, Chemaly M, Moussalli M . Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014; 16(9):439. DOI: 10.1007/s11883-014-0439-8. View

Bos S, Duvekot M, Ten Kate G, Verhoeven A, Mulder M, Schinkel A . Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study. Atherosclerosis. 2016; 256:62-66. DOI: 10.1016/j.atherosclerosis.2016.12.005. View

Li L, Shen C, Huang Y, Li Y, Liu X, Liu X . A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro. Molecules. 2018; 23(9). PMC: 6225438. DOI: 10.3390/molecules23092397. View

Song H, Wang H, Liang J, Qian C, Wu S, Xu W . Integration of Multiple Analytical and Computational Tools for the Discovery of High-Potency Enzyme Inhibitors from Herbal Medicines. ChemMedChem. 2016; 11(23):2588-2597. DOI: 10.1002/cmdc.201600489. View

10.

Wang Y, Lee S, Hsu C, Kuo Y, Yang C, Lin F . Antcins, triterpenoids from Antrodia cinnamomea, as new agonists for peroxisome proliferator-activated receptor α. J Food Drug Anal. 2019; 27(1):295-304. PMC: 9298643. DOI: 10.1016/j.jfda.2018.11.004. View

11.

Ochiai A, Miyata S, Iwase M, Shimizu M, Inoue J, Sato R . Kaempferol stimulates gene expression of low-density lipoprotein receptor through activation of Sp1 in cultured hepatocytes. Sci Rep. 2016; 6:24940. PMC: 4842988. DOI: 10.1038/srep24940. View

12.

Wang X, Ding X, Yuan Y, Zheng L, Cao Y, Zhu Z . Comprehensive two-dimensional APTES-decorated MCF7-cell membrane chromatographic system for characterizing potential anti-breast-cancer components from Yuanhu-Baizhi herbal medicine pair. J Food Drug Anal. 2018; 26(2):823-833. PMC: 9322241. DOI: 10.1016/j.jfda.2017.11.010. View

13.

Steinberg D, Witztum J . Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009; 106(24):9546-7. PMC: 2701045. DOI: 10.1073/pnas.0904560106. View

14.

Gruenbaum L, Schwartz R, Woska Jr J, DeLeon R, Peet G, Warren T . Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem Pharmacol. 2008; 77(3):422-32. DOI: 10.1016/j.bcp.2008.10.032. View

15.

Wang J, Chen J, Wang M, Fu X, Chen Y, Guo H . [Determination of 7 flavonol glycosides in Ginkgo biloba reference extract]. Zhongguo Zhong Yao Za Zhi. 2016; 40(20):4018-21. View

16.

Wood E, Truesdale A, McDonald O, Yuan D, Hassell A, Dickerson S . A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004; 64(18):6652-9. DOI: 10.1158/0008-5472.CAN-04-1168. View

17.

de Almeida F, Vanzolini K, Cass Q . Angiotensin converting enzyme immobilized on magnetic beads as a tool for ligand fishing. J Pharm Biomed Anal. 2016; 132:159-164. DOI: 10.1016/j.jpba.2016.10.006. View

18.

Lagace T, Curtis D, Garuti R, McNutt M, Park S, Prather H . Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006; 116(11):2995-3005. PMC: 1626117. DOI: 10.1172/JCI29383. View

19.

Zhou W, Chai H, Lin P, Lumsden A, Yao Q, Chen C . Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. Cardiovasc Drug Rev. 2004; 22(4):309-19. DOI: 10.1111/j.1527-3466.2004.tb00148.x. View

20.

Puri R, Nissen S, Somaratne R, Cho L, Kastelein J, Ballantyne C . Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016; 176:83-92. DOI: 10.1016/j.ahj.2016.01.019. View